Impax Pharmaceuticals Provides an Update on Pipeline Candidate IPX159
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced the successful filing of an Investigational New Drug Application (IND) for IPX159 in Restless Legs Syndrome (RLS) and initiated a Phase I study.